Delving into the Latest Updates on CMAB-820 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Non-Small Cell Lung Cancer

Inactive Indication-

Originator Organization

Shanghai Zhangjiang Biotechnology Co. Ltd.

Active Organization

Shanghai Zhangjiang Biotechnology Co. Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的比较CMAB820注射液和可瑞达®在健康成年男性受试者中单次给药的药代动力学（PK）特征的相似性次要目的比较CMAB820注射液和可瑞达®在健康成年男性受试者中单次给药的安全性和免疫原性比较CMAB820注射液和可瑞达®在健康成年男性受试者中单次给药的药效学特征

[Translation]

Primary objective To compare the similarity of the pharmacokinetic (PK) characteristics of CMAB820 injection and Keytruda® in healthy adult male subjects after a single dose Secondary objective To compare the safety and immunogenicity of CMAB820 injection and Keytruda® in healthy adult male subjects after a single dose To compare the pharmacodynamic characteristics of CMAB820 injection and Keytruda® in healthy adult male subjects after a single dose

Start Date-

Sponsor / Collaborator

Shanghai Zhangjiang Biotechnology Co. Ltd.

100 Clinical Results associated with CMAB-820

Login to view more data

100 Translational Medicine associated with CMAB-820

Login to view more data

100 Patents (Medical) associated with CMAB-820

Login to view more data

100 Deals associated with CMAB-820

Login to view more data